Significance of Resveratrol in Clinical Management of Chronic Diseases

Awais Wahab, Kuo Gao, Caixia Jia, Feilong Zhang, Guihua Tian, Ghulam Murtaza, Jianxin Chen, Awais Wahab, Kuo Gao, Caixia Jia, Feilong Zhang, Guihua Tian, Ghulam Murtaza, Jianxin Chen

Abstract

Resveratrol could be beneficial to health and provides protection against a wide array of pathologies and age-associated problems, as evident from preclinical studies. However, a comparison of animal and human studies reveals that this dietary polyphenol cannot protect against metabolic diseases and their associated complications. The clinical outcomes are affected by many factors such as sample size. This article not only presents a comprehensive review of the current advances concerning the dose, the extent of absorption, interaction and toxicity of resveratrol in human studies, but also describes its therapeutic effects against several chronic diseases such as diabetes mellitus, obesity, cardiovascular diseases, cancer and aging and the related diseases.

Keywords: absorption; aging; cancer; cardiovascular diseases; clinical studies; diabetes mellitus; obesity; pre-clinical studies; toxicity.

Conflict of interest statement

The authors declare no conflict of interest. Moreover, the founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results”.

Figures

Figure 1
Figure 1
Molecular targets of resveratrol retrieved through the STITCH 5.0 database. Note: SIRT1—sirtuin 1; ESR1—estrogen receptor 1; PPARG—peroxisome proliferator—activated receptor gamma; NOS3—nitric oxide synthase 3; SIRT5—sirtuin 5; PTGS2—prostaglandin—endoperoxide synthase 2; PTGS1—prostaglandin-endoperoxide synthase 1; AKT1—v-akt murine thymoma viral oncogene homolog 1; SIRT3—sirtuin 3; TP53—tumor protein p53; PTEN—phosphatase and tensin homolog; NQO2—NAD(P)H dehydrogenase, quinone 2; NAMPT—nicotinamide phosphoribosyltransferase; IGF1—insulin-like growth factor 1; FOXO3—forkhead box O3; FOXO1—forkhead box O1; HMOX1—heme oxygenase (decycling) 1; PPARA—peroxisome proliferator-activated receptor alpha; NFE2L2—nuclear factor (erythroid-derived 2)-like 2; CYP1A1—cytochrome P450, family 1, subfamily A, polypeptide 1.
Figure 2
Figure 2
Short review of the resveratrol effects in clinical trials in patients suffering from type 2 diabetes mellitus, obesity, cardiovascular diseases (CVD) disease, skin disorders or cancer.

References

    1. Wang S., Wang Z., Yang S., Yin T., Zhang Y., Qin Y., Weinreb R.N., Sun X. Tissue Distribution of trans-Resveratrol and Its Metabolites after Oral Administration in Human Eyes. J. Ophthalmol. Vol. 2017 doi: 10.1155/2017/4052094.
    1. Khaled K., Abu-Amero K.K., Altaf A., Kondkar A.A., Chalam V.K. Resveratrol and Ophthalmic Diseases. Nutrients. 2016;8:200. doi: 10.3390/nu8040200.
    1. Novelle M.G., Wahl D., Diéguez C., Bernier M., de Cabo R. Resveratrol supplementation: Where are we now and where should we go? Ageing Res. Rev. 2015;21:1–15. doi: 10.1016/j.arr.2015.01.002.
    1. Cottart C.H., Nivet-Antoine V., Beaudeux J.L. Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans. Mol. Nutr. Food Res. 2014;58:7–21. doi: 10.1002/mnfr.201200589.
    1. Howells L.M., Berry D.P., Elliott P.J., Jacobson E.W., Hoffmann E., Hegarty B., Brown K., Steward W.P., Gescher A.J. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases—Safety, pharmacokinetics, and pharmacodynamics. Cancer Prev. Res. 2011;4:1419–1425. doi: 10.1158/1940-6207.CAPR-11-0148.
    1. Poulsen M.M., Vestergaard P.F., Clasen B.F., Radko Y., Christensen L.P., Stodkilde-Jorgensen H., Moller N., Jessen N., Pedersen S.B., Jorgensen J.O. High-dose resveratrol supplementation in obese men: An investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes. 2013;62:1186–1195. doi: 10.2337/db12-0975.
    1. Moon R.T., Kohn A.D., De Ferrari G.V., Kaykas A. WNT and beta-catenin signalling: Diseases and therapies. Nat. Rev. Genet. 2004;5:691–701. doi: 10.1038/nrg1427.
    1. Detampel P., Beck M., Krahenbuhl S., Huwyler J. Drug interaction potential of resveratrol. Drug Metab. Rev. 2012;44:253–265. doi: 10.3109/03602532.2012.700715.
    1. Nguyen A.V., Martinez M., Stamos M.J., Moyer M.P., Planutis K., Hope C., Holcombe R.F. Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer Manag. Res. 2009;1:25–37.
    1. Miller R.A., Harrison D.E., Astle C.M., Baur J.A., Boyd A.R., de C.R., Fernandez E., Flurkey K., Javors M.A., Nelson J.F., et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J. Gerontol. A Biol. Sci. Med. Sci. 2011;66:191–201. doi: 10.1093/gerona/glq178.
    1. Strong R., Miller R.A., Astle C.M., Baur J.A., de Cabo R., Fernandez E., Guo W., Javors M., Kirkland J.L., Nelson J.F., et al. Evaluation of resveratrol, green tea extract, curcumin, oxaloacetic acid, and medium-chain triglyceride oil on life span of genetically heterogeneous mice. J. Gerontol. A Biol. Sci. Med. Sci. 2013;68:6–16. doi: 10.1093/gerona/gls070.
    1. Bhatt J.K., Thomas S., Nanjan M.J. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr. Res. 2012;32:537–541. doi: 10.1016/j.nutres.2012.06.003.
    1. Brasnyo P., Molnar G.A., Mohas M., Marko L., Laczy B., Cseh J., Mikolas E., Szijarto I.A., Merei A., Halmai R., et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br. J. Nutr. 2011;106:383–389. doi: 10.1017/S0007114511000316.
    1. Tome-Carneiro J., Larrosa M., Yanez-Gascon M.J., Davalos A., Gil-Zamorano J., Gonzalvez M., Garcia-Almagro F.J., Ruiz Ros J.A., Tomas-Barberan F.A., Espin J.C., et al. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol. Res. 2013;72:69–82. doi: 10.1016/j.phrs.2013.03.011.
    1. Dash S., Xiao C., Morgantini C., Szeto L., Lewis G.F. High-dose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men. Arterioscler. Thromb. Vasc. Biol. 2013;33:2895–2901. doi: 10.1161/ATVBAHA.113.302342.
    1. Ornstrup M.J., Harsløf T., Kjær T.N., Langdahl B.L., Pedersen S.B. Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: A randomized placebo-controlled trial. J. Clin. Endocrinol. Metab. 2014 doi: 10.1210/jc.2014-2799.
    1. Wong R.H., Howe P.R., Buckley J.D., Coates A.M., Kunz I., Berry N.M. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr. Metab Cardiovasc. Dis. 2011;21:851–856. doi: 10.1016/j.numecd.2010.03.003.
    1. Crandall J.P., Oram V., Trandafirescu G., Reid M., Kishore P., Hawkins M., Cohen H.W., Barzilai N. Pilot study of resveratrol in older adults with impaired glucose tolerance. J. Gerontol. A. Biol. Sci. Med. Sci. 2012;67:1307–1312. doi: 10.1093/gerona/glr235.
    1. Mendez del Villar M., Gonzalez-Ortiz M., Martinez-Abundis E., Perez-Rubio K.G., Lizarraga-Valdez R. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab. Syndr. Relat. Disord. 2014;12:497–501. doi: 10.1089/met.2014.0082.
    1. Chachay V.S., Macdonald G.A., Martin J.H., Whitehead J.P., O’Moore-Sullivan T.M., Lee P., Franklin M., Klein K., Taylor P.J., Ferguson M., et al. Resveratrol does not benefit patients with non-alcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2014 doi: 10.1016/j.cgh.2014.02.024.
    1. Faghihzadeh F., Adibi P., Rafiei R., Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr. Res. 2014;34:837–843. doi: 10.1016/j.nutres.2014.09.005.
    1. Patel K.R., Brown V.A., Jones D.J., Britton R.G., Hemingway D., Miller A.S., West K.P., Booth T.D., Perloff M., Crowell J.A., et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 2010;70:7392–7399. doi: 10.1158/0008-5472.CAN-10-2027.
    1. Zhu W., Qin W., Zhang K., Rottinghaus G.E., Chen Y.C., Kliethermes B., Sauter E.R. trans-Resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutr. Cancer. 2012;64:393–400. doi: 10.1080/01635581.2012.654926.
    1. Militaru C., Donoiu I., Craciun A., Scorei I.D., Bulearca A.M., Scorei R.I. Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: Effects on lipid profiles, inflammation markers, and quality of life. Nutrition. 2013;29:178–183. doi: 10.1016/j.nut.2012.07.006.
    1. Tome-Carneiro J., Gonzalvez M., Larrosa M., Yanez-Gascon M.J., Garcia-Almagro F.J., Ruiz-Ros J.A., Tomas-Barberan F.A., Garcia-Conesa M.T., Espin J.C. Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: A triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovasc. Drugs Ther. 2013;27:37–48. doi: 10.1007/s10557-012-6427-8.
    1. Magyar K., Halmosi R., Palfi A., Feher G., Czopf L., Fulop A., Battyany I., Sumegi B., Toth K., Szabados E. Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. Clin. Hemorheol. Microcirc. 2012;50:179–187.
    1. Anton S.D., Embry C., Marsiske M., Lu X., Doss H., Leeuwenburgh C., Manini T.M. Safety and metabolic outcomes of resveratrol supplementation in older adults: Results of a twelve-week, placebo-controlled pilot study. Exp. Gerontol. 2014;57:181–187. doi: 10.1016/j.exger.2014.05.015.
    1. Scribbans T.D., Ma J.K., Edgett B.A., Vorobej K.A., Mitchell A.S., Zelt J.G., Simpson C.A., Quadrilatero J., Gurd B.J. Resveratrol supplementation does not augment performance adaptations or fibre-type-specific responses to high intensity interval training in humans. Appl. Physiol. Nutr. MeTable. 2014;39:1305–1313. doi: 10.1139/apnm-2014-0070.
    1. Timmers S., Konings E., Bilet L., Houtkooper R.H., van de Weijer T., Goossens G.H., Hoeks J., van der Krieken S., Ryu D., Kersten S., et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14:612–622. doi: 10.1016/j.cmet.2011.10.002.
    1. Yoshino J., Conte C., Fontana L., Mittendorfer B., Imai S., Schechtman K.B., Gu C., Kunz I., Rossi F.F., Patterson B.W., et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab. 2012;16:658–664. doi: 10.1016/j.cmet.2012.09.015.
    1. Most J., Goossens G.H., Jocken J.W., Blaak E.E. Short-term supplementation with a specific combination of dietary polyphenols increases energy expenditure and alters substrate metabolism in overweight subjects. Int. J. Obes. 2014;38:698–706. doi: 10.1038/ijo.2013.231.
    1. Knop F.K., Konings E., Timmers S., Schrauwen P., Holst J.J., Blaak E.E. Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects. Diabet. Med. 2013;30:1214–1218. doi: 10.1111/dme.12231.
    1. Konings E., Timmers S., Boekschoten M.V., Goossens G.H., Jocken J.W., Afman L.A., Muller M., Schrauwen P., Mariman E.C., Blaak E.E. The effects of 30 days resveratrol supplementation on adipose tissue morphology and gene expression patterns in obese men. Int. J. Obes. 2014;38:470–473. doi: 10.1038/ijo.2013.155.
    1. Ghanim H., Sia C.L., Abuaysheh S., Korzeniewski K., Patnaik P., Marumganti A., Chaudhuri A., Dandona P. An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J. Clin. Endocrinol. MeTable. 2010;95:E1–E8. doi: 10.1210/jc.2010-0482.
    1. Ghanim H., Sia C.L., Korzeniewski K., Lohano T., Abuaysheh S., Marumganti A., Chaudhuri A., Dandona P. A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high carbohydrate meal. J. Clin. Endocrinol. MeTable. 2011;96:1409–1414. doi: 10.1210/jc.2010-1812.
    1. De Groote G.D., Van B.K., Deviere J., Van B.W., Mukaneza A., Amininejad L. Effect of the intake of resveratrol, resveratrol phosphate, and catechin-rich grape seed extract on markers of oxidative stress and gene expression in adult obese subjects. Ann. Nutr. MeTable. 2012;61:15–24. doi: 10.1159/000338634.
    1. Bo S., Ciccone G., Castiglione A., Gambino R., De M.F., Villois P., Durazzo M., Cavallo-Perin P., Cassader M. Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo controlled, cross-over trial. Curr. Med. Chem. 2013;20:1323–1331. doi: 10.2174/0929867311320100009.
    1. Gualdoni G.A., Kovarik J.J., Hofer J., Dose F., Pignitter M., Doberer D., Steinberger P., Somoza V., Wolzt M., Zlabinger G.J. Resveratrol enhances TNF-alpha production in human monocytes upon bacterial stimulation. Biochim. Biophys. Acta. 2014;1840:95–105. doi: 10.1016/j.bbagen.2013.09.009.
    1. Kennedy D.O., Wightman E.L., Reay J.L., Lietz G., Okello E.J., Wilde A., Haskell C.F. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: A double-blind, placebo-controlled, crossover investigation. Am. J. Clin. Nutr. 2010;91:1590–1597. doi: 10.3945/ajcn.2009.28641.
    1. Wong R.H., Berry N.M., Coates A.M., Buckley J.D., Bryan J., Kunz I., Howe P.R. hronic resveratrol consumption improves brachial flow-mediated dilatation in healthy obese adults. J. Hypertens. 2013;31:1819–1827. doi: 10.1097/HJH.0b013e328362b9d6.
    1. Wightman E.L., Reay J.L., Haskell C.F., Williamson G., Dew T.P., Kennedy D.O. Effects of resveratrol alone or in combination with piperine on cerebral blood flow parameters and cognitive performance in human subjects: A randomised, double-blind, placebo-controlled, cross-over investigation. Br. J. Nutr. 2014;112:203–213. doi: 10.1017/S0007114514000737.
    1. Witte A.V., Kerti L., Margulies D.S., Floel A. Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. J. Neurosci. 2014;34:7862–7870. doi: 10.1523/JNEUROSCI.0385-14.2014.
    1. Agarwal B., Campen M.J., Channell M.M., Wherry S.J., Varamini B., Davis J.G., Baur J.A., Smoliga J.M. Resveratrol for primary prevention of atherosclerosis: Clinical trial evidence for improved gene expression in vascular endothelium. Int. J. Cardiol. 2013;166:246–248. doi: 10.1016/j.ijcard.2012.09.027.
    1. Chow H.H., Garland L.L., Heckman-Stoddard B.M., Hsu C.H., Butler V.D., Cordova C.A., Chew W.M., Cornelison T.L. A pilot clinical study of resveratrol in postmenopausal women with high body mass index: Effects on systemic sex steroid hormones. J. Trans. Med. 2014;12:223. doi: 10.1186/s12967-014-0223-0.
    1. Amiot M.J., Romier B., Dao T.M., Fanciullino R., Ciccolini J., Burcelin R., Pechere L., Emond C., Savouret J.F., Seree E. Optimization of trans-Resveratrol bioavailability for human therapy. Biochimie. 2013;95:1233–1238. doi: 10.1016/j.biochi.2013.01.008.
    1. Bode L.M., Bunzel D., Huch M., Cho G.S., Ruhland D., Bunzel M., Bub A., Franz C.M., Kulling S. EIn vivo and in vitro metabolism of trans-resveratrol by human gut microbiota. Am. J. Clin. Nutr. 2013;97:295–309. doi: 10.3945/ajcn.112.049379.
    1. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., Prabhu V.V., Allard J.S., Lopez-Lluch G., Lewis K., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444:337–342. doi: 10.1038/nature05354.
    1. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliott P., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006;127:1109–1122. doi: 10.1016/j.cell.2006.11.013.
    1. Ramadori G., Gautron L., Fujikawa T., Vianna C.R., Elmquist J.K., Coppari R. Central administration of resveratrol improves diet-induced diabetes. Endocrinology. 2009;150:5326–5333. doi: 10.1210/en.2009-0528.
    1. Pearson K.J., Baur J.A., Lewis K.N., Peshkin L., Price N.L., Labinskyy N., Swindell W.R., Kamara D., Minor R.K., Perez E., et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008;8:157–168. doi: 10.1016/j.cmet.2008.06.011.
    1. Dolinsky V.W., Jones K.E., Sidhu R.S., Haykowsky M., Czubryt M.P., Gordon T., Dyck J.R. Improvements in skeletal muscle strength and cardiac function induced by resveratrol during exercise training contribute to enhanced exercise performance in rats. J. Physiol. 2012;590:2783–2799. doi: 10.1113/jphysiol.2012.230490.
    1. Dolinsky V.W., Chakrabarti S., Pereira T.J., Oka T., Levasseur J., Beker D., Zordoky B.N., Morton J.S., Nagendran J., Lopaschuk G.D., et al. Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. Biochim. Biophys. Acta. 2013;1832:1723–1733. doi: 10.1016/j.bbadis.2013.05.018.
    1. Della-Morte D., Dave K.R., DeFazio R.A., Bao Y.C., Raval A.P., Perez-Pinzon M.A. Resveratrol pretreatment protects rat brain from cerebral ischemic damage via a sirtuin 1-uncoupling protein 2 pathway. Neuroscience. 2009;159:993–1002. doi: 10.1016/j.neuroscience.2009.01.017.
    1. Kumar A., Negi G., Sharma S.S. Neuroprotection by resveratrol in diabetic neuropathy: Concepts & mechanisms. Curr. Med. Chem. 2013;20:4640–4645.
    1. Karuppagounder S.S., Pinto J.T., Xu H., Chen H.L., Beal M.F., Gibson G.E. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer’s disease. Neurochem. Int. 2009;54:111–118. doi: 10.1016/j.neuint.2008.10.008.
    1. Kim D., Nguyen M.D., Dobbin M.M., Fischer A., Sananbenesi F., Rodgers J.T., Delalle I., Baur J.A., Sui G., Armour S.M., et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer’s disease and amyotrophic lateral sclerosis. EMBO J. 2007;26:3169–3179. doi: 10.1038/sj.emboj.7601758.
    1. Huang T.C., Lu K.T., Wo Y.Y., Wu Y.J., Yang Y.L. Resveratrol protects rats from Abeta-induced neurotoxicity by the reduction of iNOS expression and lipid peroxidation. PLoS ONE. 2011;6:e29102. doi: 10.1371/journal.pone.0029102.
    1. Tome-Carneiro J., Larrosa M., Gonzalez-Sarrias A., Tomas-Barberan F.A., GarciaConesa M.T., Espin J.C. Resveratrol and clinical trials: The crossroad from in vitro studies to human evidence. Curr. Pharm. Des. 2013;19:6064–6093. doi: 10.2174/13816128113199990407.
    1. Oktem G., Uysal A., Oral O., Sezer E.D., Olukman M., Erol A., Akgur S.A., Bilir A. Resveratrol attenuates doxorubicin-induced cellular damage by modulating nitric oxide and apoptosis. Exp. Toxicol. Pathol. 2012;64:471–479. doi: 10.1016/j.etp.2010.11.001.
    1. Halicka H.D., Zhao H., Li J., Lee Y.S., Hsieh T.C., Wu J.M., Darzynkiewicz Z. Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage-signaling. Aging. 2012;4:952–965. doi: 10.18632/aging.100521.
    1. Kowalczyk M.C., Kowalczyk P., Tolstykh O., Hanausek M., Walaszek Z., Slaga T.J. Synergistic effects of combined phytochemicals and skin cancer prevention in SENCAR mice. Cancer Prev. Res. 2010;3:170–178. doi: 10.1158/1940-6207.CAPR-09-0196.
    1. Jung K.H., Lee J.H., Thien Quach C.H., Paik J.Y., Oh H., Park J.W., Lee E.J., Moon S.H., Lee K.H. Resveratrol suppresses cancer cell glucose uptake by targeting reactive oxygen species-mediated hypoxia-inducible factor-1alpha activation. J. Nucl. Med. 2013;54:2161–2167. doi: 10.2967/jnumed.112.115436.
    1. Boily G., He X.H., Pearce B., Jardine K., McBurney M. WSirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol. Oncogene. 2009;28:2882–2893. doi: 10.1038/onc.2009.147.
    1. Dias S.J., Li K., Rimando A.M., Dhar S., Mizuno C.S., Penman A.D., Levenson A.S. Trimethoxy-resveratrol and piceatannol administered orally suppress and inhibit tumor formation and growth in prostate cancer xenografts. Prostate. 2013;73:1135–1146. doi: 10.1002/pros.22657.
    1. Lee-Chang C., Bodogai M., Martin-Montalvo A., Wejksza K., Sanghvi M., Moaddel R., de Cabo R., Biragyn A. Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory B cells. J. Immunol. 2013;191:4141–4151. doi: 10.4049/jimmunol.1300606.
    1. Lin H.C., Chen Y.F., Hsu W.H., Yang C.W., Kao C.H., Tsai T.F. Resveratrol helps recovery from fatty liver and protects against hepatocellular carcinoma induced by hepatitis B virus X protein in a mouse model. Cancer Prev. Res. 2012;5:952–962. doi: 10.1158/1940-6207.CAPR-12-0001.
    1. Carter L.G., D’Orazio J.A., Pearson K.J. Resveratrol and cancer: A focus on in vivo evidence. Endocr. Relat. Cancer. 2014;21:R209–R225. doi: 10.1530/ERC-13-0171.
    1. Castillo-Pichardo L., Cubano L.A., Dharmawardhane S. Dietary grape polyphenol resveratrol increases mammary tumor growth and metastasis in immunocompromised mice. BMC Complement. Altern. Med. 2013;13:6. doi: 10.1186/1472-6882-13-6.
    1. Yang L., Yang L., Tian W., Li J., Liu J., Zhu M., Zhang Y., Yang Y., Liu F., Zhang Q., et al. Resveratrol plays dual roles in pancreatic cancer cells. J. Cancer Res. Clin. Oncol. 2014;140:749–755. doi: 10.1007/s00432-014-1624-4.
    1. Ndiaye M., Philippe C., Mukhtar H., Ahmad N. The grape antioxidant resveratrol for skin disorders: Promise, prospects, and challenges. Arch. Biochem. Biophys. 2011;508:164–170. doi: 10.1016/j.abb.2010.12.030.
    1. Afaq F., Adhami V.M., Ahmad N. Prevention of short-term ultraviolet B radiation-mediated damages by resveratrol in SKH-1 hairless mice. Toxicol. Appl. Pharmacol. 2003;186:28–37. doi: 10.1016/S0041-008X(02)00014-5.
    1. Ungvari Z., Csiszar A. Resveratrol confers endothelial protection in insulin dependent diabetes mellitus: Editorial to: “Resveratrol shows vasoprotective effect reducing oxidative stress without affecting metabolic disturbances in insulin-dependent diabetes of rabbits” by F. Akar et al. Cardiovasc. Drugs Ther. 2011;25:111–113.
    1. Boyle J.P., Thompson T.J., Gregg E.W., Barker L.E., Williamson D.F. Projection of the year 2050 burden of diabetes in the US adult population: Dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul. Health Metr. 2010;8:29. doi: 10.1186/1478-7954-8-29.
    1. Fiori J.L., Shin Y.K., Kim W., Krzysik-Walker S.M., Gonzalez-Mariscal I., Carlson O.D., Sanghvi M., Moaddel R., Farhang K., Gadkaree S.K., et al. Resveratrol prevents beta-cell dedifferentiation in nonhuman primates given a high-fat/high-sugar diet. Diabetes. 2013;62:3500–3513. doi: 10.2337/db13-0266.
    1. Jimenez-Gomez Y., Mattison J.A., Pearson K.J., Martin-Montalvo A., Palacios H.H., Sossong A.M., Ward T.M., Younts C.M., Lewis K., Allard J.S., et al. Resveratrol improves adipose insulin signaling and reduces the inflammatory response in adipose tissue of rhesus monkeys on high-fat, highsugar diet. Cell MeTable. 2013;18:533–545. doi: 10.1016/j.cmet.2013.09.004.
    1. Kang W., Hong H.J., Guan J., Kim D.G., Yang E.J., Koh G., Park D., Han C.H., Lee Y.J., Lee D.H. Resveratrol improves insulin signaling in a tissue-specific manner under insulin-resistant conditions only: In vitro and in vivo experiments in rodents. Metabolism. 2012;61:424–433. doi: 10.1016/j.metabol.2011.08.003.
    1. Liu K., Zhou R., Wang B., Mi M.T. Effect of resveratrol on glucose control and insulin sensitivity: A meta-analysis of 11 randomized controlled trials. Am. J. Clin. Nutr. 2014;99:1510–1519. doi: 10.3945/ajcn.113.082024.
    1. Hausenblas H.A., Schoulda J.A., Smoliga J.M. Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus-systematic review and meta-analysis. Mol. Nutr. Food Res. 2014 doi: 10.1002/mnfr.201400173.
    1. Elliot P.J., Walpole S., Morelli L., Lambert P.D., Lunsmann W., Westphal C.H. Lavu, SResveratrol/SRT-501. Drug. Future. 2009;34:291–295. doi: 10.1358/dof.2009.034.04.1360696.
    1. Kumar B.J., Joghee N.M. Resveratrol supplementation in patients with type 2 diabetes mellitus: A prospective, open label, randomized controlled trial. Int. Res. J. Pharm. 2013;4:246–249.
    1. Ángel D.V.M., Antonieta G.S.M., Rocio G.C., Jorge R.E., Rosado J.L., Lourdes R.F. Effects of Combined Resveratrol Plus Metformin Therapy in db/db Diabetic Mice. J. Metab. Syndr. 2016;5:217. doi: 10.4172/2167-0943.1000217.
    1. Movahed A., Nabipour I., Lieben L.X., Thandapilly S.J., Yu L., Kalantarhormozi M., Rekabpour S.J., Netticadan T. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid. Based Complement. Alternat. Med. 2013;2013:851267. doi: 10.1155/2013/851267.
    1. Goh K.P., Lee H.Y., Lau D.P., Supaat W., Chan Y.H., Koh A.F. Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure. Int. J. Sport Nutr. Exerc. Metab. 2014;24:2–13. doi: 10.1123/ijsnem.2013-0045.
    1. Roberts V.H., Pound L.D., Thorn S.R., Gillingham M.B., Thornburg K.L., Friedman J.E., Frias A.E., Grove K.L. Beneficial and cautionary outcomes of resveratrol supplementation in pregnant nonhuman primates. FASEB J. 2014;28:2466–2477. doi: 10.1096/fj.13-245472.
    1. Pound L.D., Comstock S.M., Grove K.L. Consumption of a Western-style diet during pregnancy impairs offspring islet vascularization in a Japanese Macaque model. Am. J. Physiol. Endocrinol. Metab. 2014;307:E115–E123. doi: 10.1152/ajpendo.00131.2014.
    1. Singh G., Pai R.S. In Vitro/in-vivo characterization of trans-resveratrol loaded nanoparticulate drug delivery system for oral administration. J. Pharm. Pharmacol. 2014;66:1062–1076.
    1. Ashraf M.J., Baweja P. Obesity: The ‘huge’ problem in cardiovascular diseases. Mol. Med. 2013;110:499–504.
    1. Yang Q., Wang H., Liu Y., Gao C., Sun L., Tao L. Resveratrol Cardioprotection Against Myocardial Ischemia/Reperfusion Injury Involves Upregulation of Adiponectin Levels and Multimerization in Type 2 Diabetic Mice. J. Cardiovasc. Pharm. 2016;68:304–312. doi: 10.1097/FJC.0000000000000417.
    1. Yeung P.K. Therapeutic Potential of Resveratrol for Cardiovascular Protection. Cardiovasc. Pharm. Open Access. 2017;6:1–2. doi: 10.4172/2329-6607.1000e134.
    1. Ahmet I., Tae H.J., Lakatta E.J., Talan M. Long-term low dose dietary resveratrol supplement reduces cardiovascular structural and functional deterioration in chronic heart failure in rats. Canadian. J. Physiol. Pharmacol. 2017;95:268–274. doi: 10.1139/cjpp-2016-0512.
    1. Sahebkar A. Effects of resveratrol supplementation on plasma lipids: A systematic review and meta-analysis of randomized controlled trials. Nutr. Rev. 2013;71:822–835. doi: 10.1111/nure.12081.
    1. Tome-Carneiro J., Gonzalvez M., Larrosa M., Garcia-Almagro F.J., Aviles-Plaza F., Parra S., Yanez-Gascon M.J., Ruiz-Ros J.A., Garcia-Conesa M.T., Tomas-Barberan F.A., et al. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: A triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Mol. Nutr. Food Res. 2012;56:810–821. doi: 10.1002/mnfr.201100673.
    1. Wang H., Yang Y.J., Qian H.Y., Zhang Q., Xu H., Li J.J. Resveratrol in cardiovascular disease: What is known from current research? Heart Fail. Rev. 2012;17:437–448. doi: 10.1007/s10741-011-9260-4.
    1. Liu Y., Ma W., Zhang P., He S., Huang D. Effect of resveratrol on blood pressure: A meta-analysis of randomized controlled trials. Clin. Nutr. 2014 doi: 10.1016/j.clnu.2014.03.009.
    1. Gregor M.F., Hotamisligil G.S. Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 2011;29:415–445. doi: 10.1146/annurev-immunol-031210-101322.
    1. Matsuda M., Shimomura I. Increased oxidative stress in obesity: Implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer. Obes. Res. Clin. Pract. 2013;7:e330–e341. doi: 10.1016/j.orcp.2013.05.004.
    1. Tome-Carneiro J., Gonzalvez M., Larrosa M., Yanez-Gascon M.J., Garcia-Almagro F.J., Ruiz-Ros J.A., Garcia-Conesa M.T., Tomas-Barberan F.A., Espin J.C. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am. J. Cardiol. 2012;110:356–363. doi: 10.1016/j.amjcard.2012.03.030.
    1. Heger A., Ferk F., Nersesyan A., Szekeres T., Kundi M., Wagner K.H., Haidinger G., Misik M., Knasmuller S. Intake of a resveratrol-containing dietary supplement has no impact on DNA stability in healthy subjects. Mutat. Res. 2012;749:82–86. doi: 10.1016/j.mrgentox.2012.07.005.
    1. Wentland A.L., Grist T.M., Wieben O. Review of MRI-based measurements of pulse wave velocity: A biomarker of arterial stiffness. Cardiovasc. Diagn. Ther. 2014;4:193–206.
    1. Mattison J.A., Wang M., Bernier M., Zhang J., Park S.S., Maudsley S., An S.S., Santhanam L., Martin B., Faulkner S., et al. Resveratrol prevents high fat/sucrose diet-induced central arterial wall inflammation and stiffening in nonhuman primates. Cell Metab. 2014;20:183–190. doi: 10.1016/j.cmet.2014.04.018.
    1. Li Y.C., Liu Y.M., Shen J.D., Chen J.J., Pei Y.P., Fang X.Y. Resveratrol ameliorates the depressive-like behaviors and metabolic abnormalities induced by chronic corticosterone injection. Molecules. 2016;21:1341. doi: 10.3390/molecules21101341.
    1. Foti Cuzzola V., Ciurleo R., Giacoppo S., Marino S., Bramanti P. Role of resveratrol and its analogues in the treatment of neurodegenerative diseases: Focus on recent discoveries. CNS Neurol. Disord. Drug Targets. 2011;10:849–862. doi: 10.2174/187152711798072310.
    1. Sun A.Y., Wang Q., Simonyi A., Sun G.Y. Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol. Neurobiol. 2010;41:375–383. doi: 10.1007/s12035-010-8111-y.
    1. Moussa C., Hebron M., Huang X., Ahn J., Rissman R.A., Aisen P.S., Turner R.S. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease. J. Neuroinflamm. 2017;14:1–8. doi: 10.1186/s12974-016-0779-0.
    1. Zhao X., Wang J., Hu S., Wang R., Mao Y., Xie J. Neuroprotective effect of resveratrol on rotenone-treated C57BL/6 mice. Neuroreport. 2017;28:498–505. doi: 10.1097/WNR.0000000000000789.
    1. Wang D., Li S.P., Fu J.S., Zhang S., Bai L., Guo L. Resveratrol Defends Blood-brain Barrier Integrity in Experimental Autoimmune Encephalomyelitis Mice. J. Neurophysiol. 2016;116:2173–2179. doi: 10.1152/jn.00510.2016.
    1. Mercken E.M., Carboneau B.A., Krzysik-Walker S.M., de Cabo R. Of mice and men: The benefits of caloric restriction, exercise, and mimetics. Ageing Res. Rev. 2012;11:390–398. doi: 10.1016/j.arr.2011.11.005.
    1. Colman R.J., Beasley T.M., Kemnitz J.W., Johnson S.C., Weindruch R., Anderson R.M. Caloric restriction reduces age-related and all-cause mortality in rhesus monkeys. Nat. Commun. 2014;5:3557. doi: 10.1038/ncomms4557.
    1. Mattison J.A., Roth G.S., Beasley T.M., Tilmont E.M., Handy A.M., Herbert R.L., Longo D.L., Allison D.B., Young J.E., Bryant M., et al. Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature. 2012;489:318–321. doi: 10.1038/nature11432.
    1. Polonini H.C., Lima L.L., Goncalves K.M., do Carmo A.M., da Silva A.D., Raposo N.R. Photoprotective activity of resveratrol analogues. Bioorg. Med. Chem. 2013;21:964–968. doi: 10.1016/j.bmc.2012.11.052.
    1. Buonocore D., Lazzeretti A., Tocabens P., Nobile V., Cestone E., Santin G., Bottone M.G., Marzatico F. Resveratrol-procyanidin blend: Nutraceutical and antiaging efficacy evaluated in a placebo controlled, double-blind study. Clin. Cosmet. Investig. Dermatol. 2012;5:159–165. doi: 10.2147/CCID.S36102.
    1. Bastianetto S., Dumont Y., Duranton A., Vercauteren F., Breton L., Quirion R. Protective action of resveratrol in human skin: Possible involvement of specific receptor binding sites. PLoS ONE. 2010;5:e12935. doi: 10.1371/journal.pone.0012935.
    1. Moyano-Mendez J.R., Fabbrocini G., De S.D., Mazzella C., Mayol L., Scognamiglio I., Carnuccio R., Ayala F., La Rotonda M.I., De Rosa G. Enhanced antioxidant effect of trans-resveratrol: Potential of binary systems with polyethylene glycol and cyclodextrin. Drug Dev. Ind. Pharm. 2014;40:1300–1307. doi: 10.3109/03639045.2013.817416.
    1. Fabbrocini G., Staibano S., De Rosa G., Battimiello V., Fardella N., Ilardi G., La Rotonda M.I., Longobardi A., Mazzella M., Siano M., et al. Resveratrol-containing gel for the treatment of acne vulgaris: A single-blind, vehicle-controlled, pilot study. Am. J. Clin. Dermatol. 2011;12:133–141. doi: 10.2165/11530630-000000000-00000.
    1. Bashmakov Y.K., Assaad-Khalil S.H., Abou S.M., Udumyan R., Megallaa M., Rohoma K.H., Zeitoun M., Petyaev I.M. Resveratrol promotes foot ulcer size reduction in type 2 diabetes patients. ISRN Endocrinol. 2014;2014:816307. doi: 10.1155/2014/816307.
    1. Gonçalves G.M.S., Barros P.P., da Silva G.H., dos Santos E.M., Minutti A.F. Formulations containing curcumin or trans-resveratrol increase dermal thickness in rats submitted to chemical peeling. J. Cosmet. Dermatol. Sci. Appl. 2017;7:14–26. doi: 10.4236/jcdsa.2017.71002.
    1. Popat R., Plesner T., Davies F., Cook G., Cook M., Elliott P., Jacobson E., Gumbleton T., Oakervee H., Cavenagh J. A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. Br. J. Haematol. 2013;160:714–717. doi: 10.1111/bjh.12154.
    1. Espinoza J.L., Trung L.Q., Inaoka P.T., Yamada K., An D.T., Mizuno S., Nakao S., Takami A. The Repeated Administration of Resveratrol Has Measurable Effects on Circulating T-Cell Subsets in Humans. Oxid. Med. Cell. Longev. 2017;2017 doi: 10.1155/2017/6781872.
    1. Chang C.H., Lee C.Y., Lu C.C., Tsai F.J., Hsu Y.M., Tsao J.W., Juan Y.N., Chiu H.Y., Yang J.S., Wang C.C. Resveratrol-induced autophagy and apoptosis in cisplatin-resistant human oral cancer CAR cells: A key role of AMPK and Akt/mTOR signaling. Int. J. Oncol. 2017:873–882. doi: 10.3892/ijo.2017.3866.
    1. Clark P.A., Bhattacharya S., Elmayan A., Darjatmoko S.R., Thuro B.A., Yan M.B., Ginkel P.R., Polans R.S., Kuo J.S. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration. J. Neurosurg. 2017;126:1448–1460. doi: 10.3171/2016.1.JNS152077.
    1. Paller C.J., Rudek M.A., Zhou X.C., Wagner W.D., Hudson T.S., Anders N., Hammers H.J., Dowling D., King S., Antonarakis E.S., et al. A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination. Prostate. 2015;75:1518–1525. doi: 10.1002/pros.23024.
    1. Warburton D.E., Nicol C.W., Bredin S.S. Health benefits of physical activity: The evidence. CMAJ. 2006;174:801–809. doi: 10.1503/cmaj.051351.
    1. Olesen J., Gliemann L., Bienso R., Schmidt J., Hellsten Y., Pilegaard H. Exercise training, but not resveratrol, improves metabolic and inflammatory status in skeletal muscle of aged men. J. Physiol. 2014;592:1873–1886. doi: 10.1113/jphysiol.2013.270256.
    1. Donato A.J., Uberoi A., Bailey D.M., Wray D.W., Richardson R.S. Exercise-induced brachial artery vasodilation: Effects of antioxidants and exercise training in elderly men. Am. J. Physiol. Heart Circ. Physiol. 2010;298:H671–H678. doi: 10.1152/ajpheart.00761.2009.
    1. Kan N.W., Ho C.S., Chiu Y.S., Huang W.C., Chen P.Y., Tung Y.T., Huang C.C. Effects of resveratrol supplementation and exercise training on exercise performance in middle-aged mice. Molecules. 2016;21:661. doi: 10.3390/molecules21050661.
    1. McAnulty L.S., Miller L.E., Hosick P.A., Utter A.C., Quindry J.C., McAnulty S.R. Effect of resveratrol and quercetin supplementation on redox status and inflammation after exercise. Appl. Physiol. Nutr. Metab. 2013;38:760–765. doi: 10.1139/apnm-2012-0455.
    1. Gliemann L., Schmidt J.F., Olesen J., Bienso R.S., Peronard S.L., Grandjean S.U., Mortensen S.P., Nyberg M., Bangsbo J., Pilegaard H., Hellsten Y. Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men. J. Physiol. 2013;591:5047–5059. doi: 10.1113/jphysiol.2013.258061.
    1. Smoliga J.M., Colombo E.S., Campen M.J. A healthier approach to clinical trials evaluating resveratrol for primary prevention of age-related diseases in healthy populations. Aging. 2013;5:495–506. doi: 10.18632/aging.100579.
    1. Tennen R.I., Michishita-Kioi E., Chua K.F. Finding a target for resveratrol. Cell. 2012;148:387–389. doi: 10.1016/j.cell.2012.01.032.
    1. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., Zipkin R.E., Chung P., Kisielewski A., Zhang L.L., et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425:191–196. doi: 10.1038/nature01960.
    1. Park S.J., Ahmad F., Philp A., Baar K., Williams T., Luo H., Ke H., Rehmann H., Taussig R., Brown A.L., et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. 2012;148:421–433. doi: 10.1016/j.cell.2012.01.017.
    1. Canto C., Jiang L.Q., Deshmukh A.S., Mataki C., Coste A., Lagouge M., Zierath J.R., Auwerx J. Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab. 2010;11:213–219. doi: 10.1016/j.cmet.2010.02.006.
    1. Um J.H., Park S.J., Kang H., Yang S., Foretz M., McBurney M.W., Kim M.K., Viollet B., Chung J. H AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes. 2010;59:554–563. doi: 10.2337/db09-0482.
    1. Price N.L., Gomes A.P., Ling A.J., Duarte F.V., Martin-Montalvo A., North B.J., Agarwal B., Ye L., Ramadori G., Teodoro J.S., et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012;15:675–690. doi: 10.1016/j.cmet.2012.04.003.
    1. Kulkarni S.S., Canto C. The molecular targets of Resveratrol. Biochim. Biophys. Acta. 2014 doi: 10.1016/j.bbadis.2014.10.005.
    1. Smoliga J.M., Vang O., Baur J.A. Challenges of translating basic research into therapeutics: Resveratrol as an example. J. Gerontol. A. Biol. Sci. Med. Sci. 2012;67:158–167. doi: 10.1093/gerona/glr062.
    1. Smoliga J.M., Blanchard O.L. Recent data do not provide evidence that resveratrol causes ‘mainly negative’ or ‘adverse’ effects on exercise training in humans. J. Physiol. 2013;591:5251–5252. doi: 10.1113/jphysiol.2013.262956.
    1. Amri A., Chaumeil J.C., Sfar S., Charrueau C. Administration of resveratrol: What formulation solutions to bioavailability limitations? J. Control. Release. 2012;158:182–193. doi: 10.1016/j.jconrel.2011.09.083.
    1. Martignoni I., Trotta V., Lee W.H., Loo C.Y., Pozzoli M., Young P.M., Scalia S., Traini D. Resveratrol solid lipid microparticles as dry powder formulation for nasal delivery, characterization and in vitro deposition study. J. Microencapsul. 2016;33:735–742. doi: 10.1080/02652048.2016.1260659.
    1. Loureiro J.A., Andrade S., Duarte A., Neves A.R., Queiroz J.F., Nunes C., Sevin E., Fenart L., Gosselet F., Coelho M.A.N., Pereira M.C. Resveratrol and Grape Extract-loaded Solid Lipid Nanoparticles for the Treatment of Alzheimer’s Disease. Molecules. 2017;22:277. doi: 10.3390/molecules22020277.
    1. Pentek T., Newenhouse E., O’Brien B., Chauhan A.S. Development of a Topical Resveratrol Formulation for Commercial Applications Using Dendrimer Nanotechnology. Molecules. 2017;22:137. doi: 10.3390/molecules22010137.
    1. La Porte C., Voduc N., Zhang G., Seguin I., Tardiff D., Singhal N., Cameron D.W. Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin. Pharm. 2010;49:449–454. doi: 10.2165/11531820-000000000-00000.
    1. MacDonald L., Foster B.C., Akhtar H. Food and therapeutic product interactions—A therapeutic perspective. J. Pharm. Pharm. Sci. 2009;12:367–377. doi: 10.18433/J30P4C.
    1. Chow H.H., Garland L.L., Hsu C.H., Vining D.R., Chew W.M., Miller J.A., Perloff M., Crowell J.A., Alberts D.S. Resveratrol modulates drug- and carcinogen metabolizing enzymes in a healthy volunteer study. Cancer Prev. Res. 2010;3:1168–1175. doi: 10.1158/1940-6207.CAPR-09-0155.
    1. De Santi S.C., Pietrabissa A., Spisni R., Mosca F., Pacifici G.M. Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xenobiotica. 2000;30:857–866. doi: 10.1080/004982500433282.
    1. Johnson J.J., Nihal M., Siddiqui I.A., Scarlett C.O., Bailey H.H., Mukhtar H., Ahmad N. Enhancing the bioavailability of resveratrol by combining it with piperine. Mol. Nutr. Food Res. 2011;55:1169–1176. doi: 10.1002/mnfr.201100117.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する